ATE468136T1 - Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion - Google Patents

Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion

Info

Publication number
ATE468136T1
ATE468136T1 AT02447005T AT02447005T ATE468136T1 AT E468136 T1 ATE468136 T1 AT E468136T1 AT 02447005 T AT02447005 T AT 02447005T AT 02447005 T AT02447005 T AT 02447005T AT E468136 T1 ATE468136 T1 AT E468136T1
Authority
AT
Austria
Prior art keywords
preventing
systemic inflammatory
pharmaceutical composition
inflammatory reaction
treating systemic
Prior art date
Application number
AT02447005T
Other languages
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Collen Res Foundation Vzw filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of ATE468136T1 publication Critical patent/ATE468136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02447005T 2001-01-11 2002-01-11 Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion ATE468136T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26140501P 2001-01-11 2001-01-11

Publications (1)

Publication Number Publication Date
ATE468136T1 true ATE468136T1 (de) 2010-06-15

Family

ID=22993164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02447005T ATE468136T1 (de) 2001-01-11 2002-01-11 Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion

Country Status (7)

Country Link
EP (1) EP1222929B8 (de)
AT (1) ATE468136T1 (de)
CY (1) CY1110781T1 (de)
DE (1) DE60236386D1 (de)
DK (1) DK1222929T3 (de)
ES (1) ES2346189T3 (de)
PT (1) PT1222929E (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
WO2004065418A1 (ja) * 2003-01-20 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗pci中和抗体
US7785594B2 (en) 2003-08-14 2010-08-31 Life Sciences Research Partners Vzw Factor VIII inhibitory antibodies with reduced glycosylation
US8119137B2 (en) * 2004-12-23 2012-02-21 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
JP2009502149A (ja) 2005-07-29 2009-01-29 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 新規な抗第ｖｉｉｉ因子抗体
CN102234641A (zh) * 2010-05-05 2011-11-09 杭州星博生物科技有限公司 一种快速获取特异性人源抗体可变区基因序列的方法
DE102013005184A1 (de) * 2013-03-20 2014-09-25 fzmb GmbH, Forschungszentrum für Medizintechnik und Biotechnologie Verfahren zur Funktionalisierung einer Oberfläche

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
ES2283308T3 (es) * 1999-07-14 2007-11-01 D. Collen Research Foundation Vzw Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.

Also Published As

Publication number Publication date
DK1222929T3 (da) 2010-09-06
EP1222929A2 (de) 2002-07-17
CY1110781T1 (el) 2015-06-10
ES2346189T3 (es) 2010-10-13
PT1222929E (pt) 2010-08-18
EP1222929A3 (de) 2002-09-18
EP1222929B8 (de) 2010-07-07
DE60236386D1 (de) 2010-07-01
EP1222929B1 (de) 2010-05-19

Similar Documents

Publication Publication Date Title
CY1110781T1 (el) Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EP1592689A4 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
NO20031331L (no) Substituerte amino-aza-cykloalkaner anvendelige mot malaria
EP1638950A4 (de) Cyclohexylglycinderivate als dipeptidylpeptidaseinhibitoren zur behandlung bzw. prevention von diabetes
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
ATE331708T1 (de) Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
NO20033220D0 (no) Inhibitorer for cruzipain og andre cysteinproteaser
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
NO934218L (no) Inhibitorer av cathepsin g og elastase for forhindring av bindevevsned-brytning
IT1317108B1 (it) Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
WO2002028829A3 (en) Peptide deformylase inhibitors
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
ATE332145T1 (de) Arzneien zur begleitenden behandlung von glaukomen
NO20032822L (no) Fremgangsmate for konsentrering av brukt syre
EP1692263A4 (de) Zusammensetzungen, verfahren und nachweistechnologien zur reiterativen oligonukleotidsynthese
ATE304545T1 (de) Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48
EP1343809A4 (de) Verfahren zur herstellung eines alpha-1-proteinaseinhibitors
DE60135665D1 (de) Neue amidino-derivate und deren verwendung als thrombin-inhibitoren
DE60202034D1 (de) Verfahren zur Herstellung von Stahlrohren
WO2001077097A3 (en) Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1222929

Country of ref document: EP